Articles On Impression Healthcare (ASX:IHL)

Highlights The ASX 200 ended in the red after trading on a weak note for most part of the session on Thursday. The ASX All Ordinaries index gained 0.62% or 43.20 points to end at 7,018.40 points. There were a few shares whic...

Incannex Healthcare (ASX: IHL) has collared ethics approval, which was the final regulatory hurdle before starting a phase 1 clinical trial of its multi-use anti-inflammatory drug IHL-675A. IHL-675A comprises a fixed dose combination of can...

The All Ordinaries Index (ASX: XAO) is wobbling today, jumping from red to green. Right now, the index is recording a 0.07% gain. But its erratic behaviour hasn’t discouraged these three All Ords stocks. They’re each leaping as much a...

Incannex Healthcare (IHL) receives ethics approval for a phase one clinical trial of its cannabinoid-based multi-use anti-inflammatory drug, IHL-675A. The trial will assess the pharmacokinetics, safety, and tolerability of the drug against...

Incannex has achieved approval to start a milestone clinical trial into its multi-use, anti-inflammatory drug to treat a range of disorders including rheumatoid arthritis. ASX biotech Incannex Healthcare (ASX:IHL) has received approval from...

The ASX will open lower this morning despite a mini rally on Wall Street Tesla’s Q2 result was a surprise Gold tumbles below US$1,700 The ASX will open lower this morning, with the July futures index pointing down by 0.50% at 8am AEST. Ov...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

The ASX cannabis sector had its growth clipped in FY22 with plenty of shares declining in the financial year. Turning to FY23, the outlook is choppy. Investors are continuing to navigate the prospects of higher inflation and/or potential...

There were mixed fortunes for ASX cannabis shares in FY22. Among the bunch there were winners and losers, all while investors navigated broad-market volatility. However, the sector wasn’t immune to selling pressure. Like most pockets of...

ASX 200 healthcare shares were defensive in June but finished the month down overall. The benchmark S&P/ASX 200 Health Care Index (ASX: XHJ) was volatile, slipping 3% in June. Nevertheless, there were some names worth mentioning. Let’...

The S&P/ASX All Ordinaries Index (ASX: XAO) slipped 9.6% over the month of June. Negative sentiment about the economic outlook was a key factor weighing down the index. Here are the five worst-performing ASX shares of the month, acco...

ShareCafeEvening Report: 3 June, 2022 by Lauren Evans   The Australian sharemarket closed higher for a third straight week after advancing on Friday’s session, which offset yesterday’s fall. At the closing bell, the ASX 200 was 0.9 per cent...

Incannex Healthcare [ASX:IHL] climbed as high as 13% on Friday after releasing a clinical trials update. The post Incannex Healthcare [ASX:IHL] Shares Up with Positive Trial Results appeared first on Money Morning Australia.

Incannex Healthcare (IHL) completes the phase two trial of its cannabinoid combination drug IHL-42X The drug was used to treat 11 patients with obstructive sleep apnoea, who were given three levels of dosage, plus a placebo Results showed...

Incannex Healthcare (ASX: IHL) has found its drug IHL-42X reduced the apnoea hypopnea index (AHI) score at the three doses it was given to obstructive sleep apnoea (OSA) patients during a phase 2 clinical trial. Incannex developed IHL-42X w...

03 June 2022 - A snapshot of the stocks on the move featuring Healius (ASX:HLS), Incannex (ASX:IHL) & FireFinch (ASX:FFX).

ShareCafeLunch Report: 3 June, 2022 by Melissa Darmawan   The Australian sharemarket jumped at the open, recovering all of yesterday’s losses in a broad-based rally. If the momentum continues, the ASX 200 is on track to extend its winning s...

Healius releases trading update Incannex reports positive Phase 2 results Healthcare services provider Healius (ASX:HLS) has released its latest trading update today, which has closely tracked the guidance provided during its Investor Day...

Actor Woody Harrelson has opened a cannabis store in West Hollywood Releaf has plans for a weed wellness retreat in Byron Bay Incannex wants to buy out APIRx   It’s not surprising that Woody Harrelson loves weed – the actor was actually...

In another significant milestone, Incannex Healthcare (ASX:IHL) says it’s received positive feedback with the US Food and Drug Administration (FDA) during discussions over its IHL-42X drug, in development to treat the obstructive sleep apno...

The Incannex Healthcare Ltd (ASX: IHL) share price is soaring during mid-afternoon trade. This follows the company’s positive pre-investigational new drug application (pre-IND) meeting with the United States Food and Drug Administration (F...

Clinical-stage cannabinoid pharmaceutical development company Incannex Healthcare (ASX: IHL) has completed a pre-investigational new drug application (pre-IND) meeting with the US Food and Drug Administration (FDA) to discuss the developmen...

Incannex Healthcare (IHL) has met with the FDA to discuss its Pre-Investigational New Drug Application (pre-IND) for the development of IHL-42X The drug is being developed to treat obstructive sleep apnoea (OSA) in adults Incannex says rep...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is out of form again and tumbling lower. At the time of writing, the benchmark index is down 1.5% to 6,961 points. Four ASX shares that are not letting that hold them back are listed...

Incannex Healthcare (ASX: IHL) has completed the share sale and purchase agreement to acquire APIRx Pharmaceuticals, which will form “the world’s largest portfolio” of patented medicinal cannabinoid (CBD) drugs and psychedelic treatments. U...

Incannex shares have rocketed higher today on news it has signed a formal deal to buy out APIRx and is set to be a global powerhouse in medicinal cannabis and psychedelics.   Investors have reacted to news that clinical stage pharmaceutical...

The Incannex Healthcare Ltd (ASX: IHL) share price is on the move today following a company’s latest acquisition. At the time of writing, the healthcare company’s shares are trading at 43 cents, up 17.81%. Incannex progresses on APIRx take...

Race Oncology is set to commence Phase 1 study of Zantrene after being given governance approval Rhythm Biosciences has filed blood test ColoSTAT with the TGA Proteomics gets $400k government funding Race Oncology (ASX:RAC) has just recei...

Incannex Healthcare (IHL) signs a business deal to buy US-based APIRx Pharmaceuticals in an all-scrip transaction worth roughly $125 million The company first flagged its plans to buy APIRx back in March and has now signed a deal to issue...

IHL’s novel drug IHL-216A could be the holy grail in concussion treatment, with promising preclinical study results showing it can restore spatial memory. Clinical stage pharmaceutical company Incannex Healthcare (ASX:IHL) has announced it...

Highlights The benchmark ASX 200 index tanked 2% to 6,978.6 in the first 15 minutes of trading. US stocks continued to witness heavy liquidation on Monday, led by selling in mega-cap growth stocks. The materials sector is the biggest...

Incannex Healthcare (IHL) announces positive findings from a preclinical study trialling its IHL-216A drug in rodent models The study compared IHL-216A to CBD and isoflurane in a study model developed with the US NFL to mimic the type of b...

Clinical stage pharmaceutical company Incannex Healthcare (ASX: IHL) has confirmed its drug candidate IHL-216A has been observed to have a strong neuroprotective effect in a widely known model of sports concussion. The pre-clinical study us...

Shares of Incannex Healthcare Ltd (ASX: IHL) are on ice today pending a company announcement. Before being placed on the backburner, the Incannex share price rested at 38 cents apiece. Zooming out, shares of the cannabis player have fal...

Incannex Healthcare (ASX: IHL) has released its March quarter (Q3 FY2022) results this week, unveiling significant progress in the company’s psychedelic-based and cannabinoid combination therapeutics over the period. In February 2022, Incan...

The company had a busy quarter of clinical research breakthroughs, listing on NASDAQ and making a play for a cannabinoid development company with a big patent portfolio. With its quarterly trading update this morning, leading ASX biotech In...

Incannex Healthcare (IHL) raises $23.6 million from investors to boost funding for its clinical trial endeavours following its recent dual-listing on the Nasdaq The company tapped shareholders for the funds through a loyalty option program...

While it hasn’t been immune to the big reset in Aussie markets, the cannabis sector has certainly remained buoyant this year. Whilst most sectors have seen last year’s gains evaporate in 2022 so far, ASX cannabis shares appear to be flow...

Highlights Biotechnology companies research living organisms to develop drugs and other products. Investing in biotechnology stocks require due diligence and caution to make a profit and avoid loss. The S&P/ASX 200 Health Care ind...

The ACIC says weed consumption increased in cities and regions ROO receives USA design patent approval for its Heat Exchange Probe EMD has launched its second ultra-pure CBD capsule, the EMD-RX7   The latest Australian Criminal Intelligen...

Highlights  Incannex has executed a term sheet to wholly acquire APIRx Pharmaceutical USA APIRx has an extensive intellectual property portfolio with 19 granted patents and 23 pending patents The acquisition is expected to increase In...

ASX Emerging Companies (XEC) index has closed 0.8% lower on Thursday Monday winners: Australian Vanadium Limited (ASX:AVL), Roots Sustainable Agricultural Technologies (ASX:ROO)  Monday losers: Hawsons Iron Ore (ASX:HIO), Icannex Healthcar...

Incannex Healthcare (IHL) completes its acquisition of APIRx Pharmaceutical, a biotechnology company focused on research, development and production of prescription pharmaceutical cannabinoid medicines The purchase price of US$93.3 million...

Melbourne-based pharmaceutical company Incannex (ASX: IHL) is in a US$93.3 million (AUD$124 million) deal to acquire a US biotech outfit with intellectual property (IP) in the medicinal cannabis space.  Incannex, which is developing medici...

The Incannex Healthcare Ltd (ASX: IHL) share price is having a tough time this morning. It sunk 7% from the open before recovering most of its losses and is now 0.71% in the red at 69.5 cents. Investors are pushing Incannex shares lower af...

Incannex Healthcare (ASX: IHL) has announced a deal to acquire APIRx Pharmaceutical USA in an all scrip (share consideration) deal to affirm its position as a global leader in the fields of cannabinoid, psychedelic and combination pharmaceu...

The Incannex Healthcare Ltd (ASX: IHL) share price won’t be going anywhere on Tuesday. This comes as the company requested that its shares be placed in a trading halt. At the time of writing, the medicinal cannabis company’s shares are fro...

Shares in Incannex Healthcare Ltd (ASX: IHL) are pushing higher today and now trade almost 5% in the green at 69 cents apiece. The Incannex share price has now climbed more than 50% this past week of trade and has locked an 11% gain for t...

The Incannex Healthcare Ltd (ASX: IHL) share price is wobbling today following a company announcement regarding loyalty options. In the first hour of morning trade, the medicinal cannabis company’s shares were trading as low as 60 cents —...

Medical cannabis company Incannex Healthcare Limited (IHL) plans a loyalty issue of options to all shareholders in Australia or New Zealand Loyalty options will be issued based on shareholdings as of 5pm AEDT March 23, 2022, with one free...